Novo Nordisk A/S (NYSE:NVO) Position Reduced by Cetera Investment Advisers

Cetera Investment Advisers cut its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 12.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 250,482 shares of the company's stock after selling 36,846 shares during the quarter. Cetera Investment Advisers' holdings in Novo Nordisk A/S were worth $21,546,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVO. GQG Partners LLC lifted its position in shares of Novo Nordisk A/S by 74.7% during the 4th quarter. GQG Partners LLC now owns 12,994,533 shares of the company's stock valued at $1,117,790,000 after acquiring an additional 5,556,460 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at $404,910,000. Loomis Sayles & Co. L P increased its stake in Novo Nordisk A/S by 34.2% in the 4th quarter. Loomis Sayles & Co. L P now owns 11,571,686 shares of the company's stock worth $995,397,000 after purchasing an additional 2,947,771 shares in the last quarter. Clearbridge Investments LLC raised its holdings in Novo Nordisk A/S by 59.8% during the 4th quarter. Clearbridge Investments LLC now owns 4,283,317 shares of the company's stock worth $368,451,000 after buying an additional 1,602,549 shares during the period. Finally, Bank of America Corp DE lifted its stake in Novo Nordisk A/S by 8.1% during the fourth quarter. Bank of America Corp DE now owns 15,492,384 shares of the company's stock valued at $1,332,655,000 after buying an additional 1,165,955 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 4.1 %

NVO opened at $64.78 on Friday. The company has a market capitalization of $290.72 billion, a PE ratio of 19.69, a price-to-earnings-growth ratio of 0.90 and a beta of 0.65. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a fifty-two week low of $57.00 and a fifty-two week high of $148.15. The business has a 50-day moving average of $69.65 and a 200-day moving average of $86.58.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, meeting the consensus estimate of $0.92. The firm had revenue of $11.87 billion for the quarter, compared to analyst estimates of $79.17 billion. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a research report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday, April 25th. Guggenheim cut Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Stifel Nicolaus lowered Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Finally, Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Two research analysts have rated the stock with a sell rating, five have issued a hold rating, five have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $135.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.